ENDPOINTS

IN8bio’s Phase 1 AML data; Layoffs at Q32 Bio and Third Harmonic

Plus, news about Arvinas and Invizyne Technologies: IN8bio’s Phase 1 data in acute myeloid leukemia: In an investigator-sponsored study, all nine patients who received the company’s allogeneic gamma-delta T cell therapy

Feb 11, 2025 - 16:24
 0
IN8bio’s Phase 1 AML data; Layoffs at Q32 Bio and Third Harmonic
Plus, news about Arvinas and Invizyne Technologies: IN8bio’s Phase 1 data in acute myeloid leukemia: In an investigator-sponsored study, all nine patients who received the company’s allogeneic gamma-delta T cell therapy
Read More

Tags:

Previous Article

Updated: Judge halts NIH cuts nationwide after groups, 22 states sue

Next Article

Why you should look beyond happiness for a good life

Related Posts

Personify Health shares 2024 revenue, profitability

Personify Health shares 2024 revenue, profitability

Feb 9, 2025  0

Sionna inks $191M IPO for cystic fibrosis pipeline as Aardvark eyes $89M for its own listing

Sionna inks $191M IPO for cystic fibrosis pipeline as A...

Feb 9, 2025  0

AstraZeneca takes $753M charge on abandoned complement drug from Alexion deal

AstraZeneca takes $753M charge on abandoned complement ...

Feb 9, 2025  0